title: Stroke patient evaluation in the emergency department before pharmacologic therapy.
abstract: The standard of care for acute thromboembolic stroke is changing rapidly with the advent of new pharmacologic therapies. The deterioration of focal cerebral ischemia to infarction can be lessened with timely restoration of cerebral blood flow. As pharmacologic therapy of acute stroke evolves, emergency physicians will increasingly facilitate its implementation. The purpose of this study was to elucidate those factors significantly affecting the acute stroke patient's emergency department (ED) evaluation time. The pretreatment ED evaluations of 20 patients entered in an ongoing trial of a fibrinolytic agent (ancrod) for acute ischemic stroke were reviewed. Pretreatment screening factors included the assessment of hematologic status, concurrent illness, and potential neoplastic disease or cerebral hemorrhage as the etiology for the neurological deficit. The following factors had a statistically significant effect on pretreatment evaluation time (range, 2.6 to 11.4 hours) by multiple linear regression analysis: time from arrival until bleeding time completed (P less than .005), time from arrangement of computed head tomography until its completion (P less than .05), chosen site of treatment (ED v neurological step-down unit; P less than .005), order of patient entry (P less than .01), and time from arrival until completion of fibrinogen level assay (P less than .05). These results emphasize the need to coordinate and streamline the clinical evaluation process. The use of the ED as the site of treatment, abbreviating the time until pharmacologic therapy, has not been previously documented. Expedient completion of an evaluation compatible with safe pharmacologic therapy of acute ischemic stroke will dictate the time of definitive therapy. These results should assist other institutions considering rapid pharmacologic therapy for acute ischemic stroke.
authors.affiliation: Department of Emergency Medicine, University of Cincinnati, Cincinnati.
authors.forename: B L
authors.initials: BL
authors.lastname: Timerding
authors.forename: W G
authors.initials: WG
authors.lastname: Barsan
authors.forename: J R
authors.initials: JR
authors.lastname: Hedges
authors.forename: T G
authors.initials: TG
authors.lastname: Brott
authors.forename: P F
authors.initials: PF
authors.lastname: VanLigten
authors.forename: J A
authors.initials: JA
authors.lastname: Spilker
authors.forename: C P
authors.initials: CP
authors.lastname: Olinger
mesh_terms: D000721:Ancrod / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004636:Emergency Service, Hospital / Q000458:organization & administration*; D006801:Humans; D013997:Time Factors
chemical_list: D000721:Ancrod